Table 4.
Registries Reporting on LAAC
| Registry | Country | Years | Setting | Study Aim | Patient Characteristics | No. of AF Patients | Female (%) | Mean Age (±SD) | Paroxysmal AF (%) | CHADS2 (CHA2DS2VASC) |
|---|---|---|---|---|---|---|---|---|---|---|
| ACP37 | Europe | May 2010–June 2017 | Patients with AF at a high risk of stroke | Initial experience with ACP in European patients | On warfarin or dabigatran therapy, CHADS2 score ≥2 | 143 | — | — | — | — |
| ASAP38 | Europe | Jan 2009–Dec 2013 | Patients contraindicated for long‐term warfarin therapy | Safety and efficacy of LAAC in patients | AF contraindicated for warfarin | 150 | — | 73 (±7.4) | — | 2.8 (4.4) |
ACP indicates Amplatzer cardiac plug; AF, atrial fibrillation; ASA, acetylsalicylic acid; LAAC, left atrial appendage closure.